Tenderwize
Retour à la recherche

Open-House Discount Agreement for Abaloparatid

Techniker Krankenkasse·Hamburg, Germany·Deadline Feb 28, 2028 · 551 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-01 - Abaloparatid

30/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

30 / 100

Complexité

25 / 100

Facteurs de risque

No estimated contract value provided. The financial opportunity cannot be assessed.

Submission must be via email with qualified electronic signature or postal mail with scan. Not using standard e-procure...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Feb 2028
  • Supply of pharmaceutical products containing Abaloparatid to German statutory health insurance funds.
  • Conclusion of discount agreements under § 130c SGB V with uniform conditions.
Afficher le résumé complet

Open-house procedure for discount agreements (Rabattverträge) for the active substance Abaloparatid under § 130c SGB V. The contracting authority is Techniker Krankenkasse (TK) together with HEK and hkk. This is not a standard public procurement but an open-house model where any eligible pharmaceutical entrepreneur can join during the contract term. The contract runs from 01.03.2026 to 29.02.2028 (max 24 months). No estimated value is provided. Participation is limited to pharmaceutical entrepreneurs with a valid marketing authorization for Abaloparatid. Submission is via email or post, not through the e-procurement portal.

Risques

No estimated contract value provided. The financial opportunity cannot be assessed.

Submission must be via email with qualified electronic signature or postal mail with scan. Not using standard e-procure...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG.
  • Must have a valid marketing authorization for the medicinal product containing Abaloparatid.
  • Must be established in Germany, EU, or EEA.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria – open-house model, all eligible participants are accepted.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open-House Discount Agreement for Abaloparatid

Conclusion of discount agreements for the active substance Abaloparatid under § 130c SGB V. Open-house procedure with no exclusivity. Any pharmaceutical entrepreneur meeting eligibility criteria may join at any time during the contract term.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Feb 2026 - Feb 2028

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria – open-house model, all eligible participants are accepted.

Date limite

Deadline Feb 28, 2028

Détails de la procédure

Date de publication
27 Jan 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
62082-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3